ArticleCell biochemistry and biophysics2025
Native Fluorescence Characterization of Blood Plasma for Early Diagnosis of Oral Potentially Malignant Disorders.
Article in Cell biochemistry and biophysics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral potentially malignant disorders (PMD) are heterogenous group of oral conditions characterized by increased risk of malignant transformation that are commonly diagnosed clinically and treated. Tissue biopsy is an invasive tool for diagnosis of oral PMDs. Native fluorescence spectroscopy of biofluids has been considered as an alternative and/or complimentary tool in the characterization of tissues of various pathological conditions. In the present study, it is primarily aimed to characterize different fluorophores present in the blood plasma of normal subjects and PMD patients, using excitation-emission matrix (EEM) and to compare their diagnostic potentials in delineating PMD cases from normal subjects. From EEM measurements of blood plasma, it was observed that there is a maximum emission around 340 ± 5 nm at 307 ± 3 nm excitation for normal subjects and around 337 ± 5 nm emission at 300 ± 3 nm excitation for PMD patients. In addition to the maxima, the contours exhibit other secondary emissions such as 480 ± 5 nm at 335 ± 3 nm excitation for both normal and PMD blood plasma. It was also observed that an emission at 520 ± 5 nm for 440 ± 3 nm excitation is seen for PMD blood plasma and the same is absent in the cases of normal blood plasma. The three contours centred around 340, 480 and 520 nm may be attributed to emissions from tryptophan, NADH and FAD, respectively. Results of stepwise multiple linear discriminant analysis reveal that fluorescence spectral features of NADH classify samples more effectively with 100% sensitivity and 95% specificity.
Indexed as
Identifiers
40389793What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.